ATE418991T1 - Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker - Google Patents

Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker

Info

Publication number
ATE418991T1
ATE418991T1 AT03724098T AT03724098T ATE418991T1 AT E418991 T1 ATE418991 T1 AT E418991T1 AT 03724098 T AT03724098 T AT 03724098T AT 03724098 T AT03724098 T AT 03724098T AT E418991 T1 ATE418991 T1 AT E418991T1
Authority
AT
Austria
Prior art keywords
beta blocker
cardiac rhythm
rhythm disorders
treating cardiac
adenosine agonist
Prior art date
Application number
AT03724098T
Other languages
German (de)
English (en)
Inventor
Luiz Belardinelli
Arvinder Dhalla
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE418991T1 publication Critical patent/ATE418991T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT03724098T 2002-04-18 2003-04-18 Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker ATE418991T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37376602P 2002-04-18 2002-04-18

Publications (1)

Publication Number Publication Date
ATE418991T1 true ATE418991T1 (de) 2009-01-15

Family

ID=29251078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03724098T ATE418991T1 (de) 2002-04-18 2003-04-18 Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker

Country Status (17)

Country Link
US (3) US7005425B2 (enExample)
EP (1) EP1494685B1 (enExample)
JP (1) JP2005530736A (enExample)
KR (1) KR20040106354A (enExample)
CN (2) CN1646142A (enExample)
AT (1) ATE418991T1 (enExample)
AU (1) AU2003235466C1 (enExample)
CA (1) CA2482928A1 (enExample)
DE (1) DE60325572D1 (enExample)
ES (1) ES2318129T3 (enExample)
IL (1) IL164652A0 (enExample)
MX (1) MXPA04010285A (enExample)
NO (1) NO20045005L (enExample)
NZ (1) NZ536001A (enExample)
RU (1) RU2332220C2 (enExample)
WO (1) WO2003088978A1 (enExample)
ZA (1) ZA200408411B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1344135A (zh) 1999-03-23 2002-04-10 詹姆斯库克大学 器官的停止、保护和保存
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
RU2332220C2 (ru) * 2002-04-18 2008-08-27 Си Ви Терапьютикс, Инк. Способ снижения частоты сердечных сокращений, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
GB2436255B (en) * 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2573682A1 (en) * 2004-07-12 2006-02-16 Cv Therapeutics, Inc. Process for the preparation of a1 adenosine receptor agonists
US20060019954A1 (en) * 2004-07-20 2006-01-26 Cedars-Sinai Medical Center Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7300923B2 (en) * 2004-08-30 2007-11-27 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
JP4933435B2 (ja) 2004-09-14 2012-05-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト 遺伝子ターゲティングに基づくブシンドロール処置方法
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
JP2009538834A (ja) 2006-05-29 2009-11-12 ハイバーネイション セラピューティクス リミテッド 組織維持の改善
SG173404A1 (en) 2006-07-25 2011-08-29 Hibernation Therapeutics Ltd Trauma therapy
CA2717162A1 (en) 2007-03-02 2008-09-12 Hibernation Therapeutics Limited Transplants
JP5623288B2 (ja) 2007-12-21 2014-11-12 エイオーピーオーファン ファーマスーティカルズ アクチエンゲゼルシャフトＡＯＰ Ｏｒｐｈａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 医薬組成物
WO2010037122A1 (en) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
GB0903299D0 (en) 2009-02-26 2009-04-08 Guys And St Thomas Nhs Foundat Composition and methods
CA2835771C (en) * 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US20110039799A1 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
EA025415B1 (ru) 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
ES2613255T3 (es) 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones combinadas de agonistas de adenosina A1 y bloqueadores de receptores ß-adrenérgicos no selectivos para reducir la presión intraocular
WO2011119969A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
HRP20171204T1 (hr) 2012-01-26 2017-10-06 Inotek Pharmaceuticals Corporation Anhidridni polimorfi od [(2r,3s,4r,5r)-5-(6-(ciklopentilamino)-9h-purin- 9-il)-3,4-dihidroksitetrahidrofuran-2-il)]metil-nitrata i postupci njihove proizvodnje
EA201591433A1 (ru) 2013-03-15 2015-12-30 Инотек Фармасьютикалс Корпорейшн Офтальмологические составы
EP3021856B1 (en) 2013-07-17 2020-10-07 Hibernation Therapeutics, a KF LLC Composition for inducing organ arrest and protection, preservation and reduction of tissue injury
AU2014361813A1 (en) * 2013-12-13 2016-07-28 Ralph ANKENMAN Compositions and methods for treating dysregulated systems
CN109069495A (zh) 2016-02-01 2018-12-21 英凯达治疗公司 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常
CN106370754B (zh) * 2016-11-07 2019-03-08 西安科技大学 基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法
CN110869018A (zh) 2017-05-10 2020-03-06 英凯达治疗公司 通过肺部施用治疗心脏病况的单位剂量、气雾剂、试剂盒和方法
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
JP2000510155A (ja) * 1996-06-28 2000-08-08 メルク エンド カンパニー インコーポレーテッド 医薬製剤
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
EP0966274B1 (en) * 1997-01-31 2002-06-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
ATE262339T1 (de) * 2000-09-08 2004-04-15 Cv Therapeutics Inc Purinriboside als antiarrhythmika
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
RU2332220C2 (ru) * 2002-04-18 2008-08-27 Си Ви Терапьютикс, Инк. Способ снижения частоты сердечных сокращений, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом

Also Published As

Publication number Publication date
US20090118221A1 (en) 2009-05-07
US7005425B2 (en) 2006-02-28
EP1494685B1 (en) 2008-12-31
RU2332220C2 (ru) 2008-08-27
DE60325572D1 (de) 2009-02-12
US7479485B2 (en) 2009-01-20
NO20045005L (no) 2004-11-17
JP2005530736A (ja) 2005-10-13
CN101385738A (zh) 2009-03-18
AU2003235466C1 (en) 2008-03-20
ES2318129T3 (es) 2009-05-01
CA2482928A1 (en) 2003-10-30
CN1646142A (zh) 2005-07-27
IL164652A0 (en) 2005-12-18
RU2004130826A (ru) 2005-05-10
ZA200408411B (en) 2006-02-22
US20030216349A1 (en) 2003-11-20
WO2003088978A1 (en) 2003-10-30
EP1494685A1 (en) 2005-01-12
KR20040106354A (ko) 2004-12-17
MXPA04010285A (es) 2005-02-03
US20060052333A1 (en) 2006-03-09
AU2003235466A1 (en) 2003-11-03
NZ536001A (en) 2006-05-26

Similar Documents

Publication Publication Date Title
ATE418991T1 (de) Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
ZA200409388B (en) Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
IL157841A0 (en) Activation of natural killer cells by adenosine a3 receptor agonists
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
BR0316157A (pt) Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
MY151032A (en) Treatment of tnf? related disorders
DOP2000000107A (es) Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE318135T1 (de) Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
PL376346A1 (en) Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
EP2737904A3 (en) Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
MY146601A (en) Chemokine receptor antagonists and methods of use therefor
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
BR0307413A (pt) Terapêutica com bloqueadores de aldosterona para prevenção ou tratamento de patologias relacionadas com inflamação
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties